RT Journal Article
T1 Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
A1 Mena-Vazquez, Natalia
A1 Fernandez-Nebro, Antonio
A1 Pego-Reigosa, Jose Maria
A1 Galindo, Maria
A1 Melissa-Anzola, Ana
A1 Uriarte-Isacelay, Esther
A1 Olive-Marques, Alejandro
A1 Aurrecoechea, Elena
A1 Freire, Mercedes
A1 Tomero, Eva
A1 Garcia-Villanueva, Maria Jesus
A1 Stoye, Claudia
A1 Salas-Heredia, Esteban
A1 Bernal-Vidal, Jose Antonio
A1 Salgado, Eva
A1 Blanco, Ricardo
A1 Novoa, Francisco Javier
A1 Ibañez-Barcelo, Monica
A1 Torrente-Segarra, Vicente
A1 Narvaez, Javier
A1 Calvet, Joan
A1 Moriano-Morales, Clara
A1 Vazquez-Rodriguez, Tomas Ramon
A1 Garcia-de-la-Peña, Paloma
A1 Bohorquez, Cristina
A1 Andreu-Sanchez, Jose Luis
A1 Cobo-Ibañez, Tatiana
A1 Bonilla, Gema
A1 Lozano-Rivas, Nuria
A1 Montilla, Carlos
A1 Toyos, Francisco Javier
A1 De-la-Fuente, Jose Luis Marenco
A1 Exposito, Lorena
A1 Ruiz-Lucea, Maria Esther
A1 Vals, Elia
A1 Manero-Ruiz, Javier
A1 Bernal-Vidal, Jose A
A1 Rua-Figueroa, Iñigo
K1 Multiple autoimmune syndrome
K1 Polyautoimmunity
K1 Systemic lupus erythematosus
K1 Área de Gestión Sanitaria Sur de Sevilla
AB This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.
PB Oxford University Press
YR 2019
FD 2019-10-18
LK http://hdl.handle.net/10668/14796
UL http://hdl.handle.net/10668/14796
LA en
NO Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, Galindo M, Melissa-Anzola A, Uriarte-Isacelay E, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology (Oxford). 2020 Aug 1;59(8):2043-2051
DS RISalud
RD Apr 17, 2025